IL154114A0 - Composition for use as a medicament for increasing levels of endogeneous growth hormone - Google Patents

Composition for use as a medicament for increasing levels of endogeneous growth hormone

Info

Publication number
IL154114A0
IL154114A0 IL15411498A IL15411498A IL154114A0 IL 154114 A0 IL154114 A0 IL 154114A0 IL 15411498 A IL15411498 A IL 15411498A IL 15411498 A IL15411498 A IL 15411498A IL 154114 A0 IL154114 A0 IL 154114A0
Authority
IL
Israel
Prior art keywords
endogeneous
medicament
composition
growth hormone
increasing levels
Prior art date
Application number
IL15411498A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL154114A0 publication Critical patent/IL154114A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15411498A 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone IL154114A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IL154114A0 true IL154114A0 (en) 2003-07-31

Family

ID=21967444

Family Applications (7)

Application Number Title Priority Date Filing Date
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Growth hormone secretagogues for use in the treatment of sleep disorders
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Growth hormone secretagogues for use in the treatment of sleep disorders
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues

Country Status (40)

Country Link
US (3) US6448263B1 (enExample)
EP (1) EP1000085B1 (enExample)
JP (2) JP2000514099A (enExample)
KR (1) KR20010014224A (enExample)
CN (2) CN1152049C (enExample)
AP (1) AP1145A (enExample)
AR (1) AR012256A1 (enExample)
AT (1) ATE305477T1 (enExample)
AU (1) AU747510B2 (enExample)
BG (1) BG104008A (enExample)
BR (1) BR9810477A (enExample)
CA (1) CA2294464A1 (enExample)
CO (1) CO4950621A1 (enExample)
DE (1) DE69831745T2 (enExample)
DZ (1) DZ2539A1 (enExample)
EA (1) EA002089B1 (enExample)
EG (1) EG21712A (enExample)
ES (1) ES2248899T3 (enExample)
HN (1) HN1998000088A (enExample)
HR (1) HRP980361A2 (enExample)
HU (1) HUP0001922A3 (enExample)
ID (1) ID24345A (enExample)
IL (7) IL154114A0 (enExample)
IN (1) IN189724B (enExample)
IS (1) IS5275A (enExample)
MA (1) MA24581A1 (enExample)
NO (1) NO996205D0 (enExample)
NZ (1) NZ500655A (enExample)
OA (1) OA11242A (enExample)
PA (1) PA8452601A1 (enExample)
PE (1) PE105399A1 (enExample)
PL (1) PL337659A1 (enExample)
SK (1) SK175699A3 (enExample)
TN (1) TNSN98113A1 (enExample)
TR (1) TR199903257T2 (enExample)
TW (1) TW553943B (enExample)
UA (1) UA64751C2 (enExample)
WO (1) WO1998058949A1 (enExample)
YU (1) YU70199A (enExample)
ZA (1) ZA985546B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ES2489522T3 (es) * 2004-12-21 2014-09-02 Hercules Incorporated Resinas catiónicas reactivas para usarse como agentes de resistencia secos y húmedos en sistemas de fabricación de papel que contienen iones sulfito
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
KR102221002B1 (ko) * 2013-05-28 2021-02-26 라퀄리아 파마 인코포레이티드 다형체
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
EP3212648A1 (en) * 2014-10-31 2017-09-06 RaQualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
CN1174504A (zh) 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
CZ195098A3 (cs) 1995-12-22 1998-10-14 Novo Nordisk A/S Sloučeniny uvolňující růstový hormon
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
USRE38524E1 (en) * 1997-06-25 2004-06-01 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues

Also Published As

Publication number Publication date
SK175699A3 (en) 2001-04-09
IS5275A (is) 1999-11-26
US20030100561A1 (en) 2003-05-29
IL154111A0 (en) 2003-07-31
EA002089B1 (ru) 2001-12-24
CO4950621A1 (es) 2000-09-01
EP1000085A1 (en) 2000-05-17
EA199901075A1 (ru) 2000-08-28
HK1028051A1 (en) 2001-02-02
YU70199A (sh) 2003-01-31
NZ500655A (en) 2002-02-01
HUP0001922A3 (en) 2001-02-28
OA11242A (en) 2003-07-23
ES2248899T3 (es) 2006-03-16
KR20010014224A (ko) 2001-02-26
IL156465A0 (en) 2004-01-04
NO996205L (no) 1999-12-15
ID24345A (id) 2000-07-13
NO996205D0 (no) 1999-12-15
US6630487B2 (en) 2003-10-07
JP2005097261A (ja) 2005-04-14
IL154116A0 (en) 2003-07-31
JP3742643B2 (ja) 2006-02-08
DE69831745T2 (de) 2006-08-31
IL154115A0 (en) 2003-07-31
TR199903257T2 (xx) 2000-12-21
CA2294464A1 (en) 1998-12-30
US6867202B1 (en) 2005-03-15
DZ2539A1 (fr) 2003-02-08
PL337659A1 (en) 2000-08-28
ZA985546B (en) 2000-01-10
BR9810477A (pt) 2007-05-22
IL156465A (en) 2004-07-25
AU7445698A (en) 1999-01-04
CN1530107A (zh) 2004-09-22
AU747510B2 (en) 2002-05-16
CN1152049C (zh) 2004-06-02
EG21712A (en) 2002-02-27
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
PA8452601A1 (es) 2000-05-24
AR012256A1 (es) 2000-09-27
US6448263B1 (en) 2002-09-10
BG104008A (en) 2000-07-31
PE105399A1 (es) 1999-11-04
EP1000085B1 (en) 2005-09-28
HRP980361A2 (en) 1999-02-28
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
IN189724B (enExample) 2003-04-19
HN1998000088A (es) 1999-01-08
ATE305477T1 (de) 2005-10-15
AP1145A (en) 2003-02-14
JP2000514099A (ja) 2000-10-24
WO1998058949A1 (en) 1998-12-30
MA24581A1 (fr) 1998-12-31
UA64751C2 (uk) 2004-03-15
TW553943B (en) 2003-09-21
CN1259140A (zh) 2000-07-05
DE69831745D1 (de) 2006-02-09
TNSN98113A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
IL154114A0 (en) Composition for use as a medicament for increasing levels of endogeneous growth hormone
ZA987800B (en) Pharmaceutical composition of meloxicam
AU2695795A (en) Piperazine compounds promote release of growth hormone
HUP9900870A3 (en) Composition for sustained release of human growth hormone
IL134719A0 (en) FRACTURE HEALING USING PTHrP ANALOGS
AU5924798A (en) Fitting for dental syringe tip
IL142807A0 (en) Controlled delivery of active agents
IL133420A0 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
IL116743A0 (en) Pharmaceutical composition comprising a growth hormone
AU1403199A (en) Local delivery of therapeutic agents
HUP0200416A3 (en) Pharmaceutical composition useful for low dose estrogen interrupted hormone replacement therapy
AU9252998A (en) Implant syringe
AU686962B2 (en) Pharmaceutical preparation containing human growth hormone
AU6175398A (en) New delivery system for administering dentin-hypersensitivity-ameliorating compositions
GB9900227D0 (en) Use of a composition
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
AU8577098A (en) Needle for iontophoretic delivery of agent
AU1942995A (en) New use of growth hormone
IL147496A0 (en) Preparation of a therapeutic composition
HUP9602024A3 (en) Pharmaceutical composition containing aminoacid for external use
PL329838A1 (en) Vial for use as a complement part of syringe
HUP0102191A3 (en) Use of oxazolidinones for the preparation of a medicament for transdermal delivery
EP1007125A4 (en) CONTROLLING GAS OR MEDICINE ADMINISTRATION TO A PATIENT
IL116742A0 (en) Pharmaceutical composition comprising a growth hormone
IL116741A0 (en) Pharmaceutical composition comprising a growth hormone